Enfuvirtide
Also known as Fuzeon, T-20
Enfuvirtide (Fuzeon) is an approved HIV medicine that blocks the virus from entering your cells — used when other HIV drugs stop working.
How one dose clears
modeled over ~6 half-lives- Half-life
- 3.8 h
- Time to peak (Tmax)
- 6.0 h
- Bioavailability
- 84%
- Typical dose
- 90 mg
HIV-1 fusion inhibitor peptide for treatment-experienced patients with resistant virus. Dosed 90 mg subcutaneously twice daily.
Mechanism of action
Binds gp41 to block the conformational change HIV-1 needs to fuse with and enter host cells.
Approved drug (Fuzeon). Injection-site reactions are common. Half-life ~3.8 h (twice-daily dosing).
References
Track Enfuvirtide for free
Log your doses and PeptideBuddy models Enfuvirtide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking freeFree. No card required.